Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010022 | 0.85 | ALDH1A1 (0.44) | MEN1MAPTKMT2AALDH1A1RECQL | |
| SCHEMBL37695 | 0.84 | KDM4E (0.44) | MAPTKDM4EALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL15741057 | 0.82 | CCR5 (0.47) | MEN1MAPTKMT2AGAA | |
| SCHEMBL12117392 | 0.81 | BCL2 (0.44) | MAPTALDH1A1POLBALOX5 | |
| SCHEMBL10537568 | 0.81 | ESR1 (0.48) | ESR1ESR2KEAP1ALOX15MEN1 | |
| SCHEMBL180996 | 0.79 | SLC5A1 (0.46) | MEN1MAPTKMT2AGAAHTT | |
| SCHEMBL12363975 | 0.79 | SLC6A4 (0.47) | MEN1MAPTKMT2AALDH1A1GAA | |
| SCHEMBL20044908 | 0.79 | ESR1 (0.54) | ESR1ESR2KEAP1MEN1MAPT | |
| SCHEMBL3769930 | 0.79 | ESR1 (0.45) | ESR1ESR2KEAP1MEN1MAPT | |
| SCHEMBL18305 | 0.79 | MEN1 (0.46) | ESR1ESR2KEAP1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| EP-1924571-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7683160-B2 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-6936590-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1224195-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6774112-B2 | ANTIDIABETIC AGENTS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1385856-A2 | AMINO ACID COMPLEXES OF C-ARYL GLUCOSIDES FOR TREATMENT OF DIABETES AND METHOD | Bristol-Myers Squibb Company (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | disclosed |
| US-20030064935-A1 | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| WO-2002083066-A2 | AMINO ACID COMPLEXES OF C-ARYL GLUCOSIDES FOR TREATMENT OF DIABETES AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1224195-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414126-B1 | ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, UGGT1 | ESR1 2322/4885ESR2 940/4885KEAP1 215/4885 |
| US-20030064935-A1 | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method | SLC5A2, SLC5A1, OGFR | ESR1 2340/4885ESR2 726/4885KEAP1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.